Polycystic ovary syndrome (PCOS) appears to result from increase of GnRH activity and LH release, as well as elevated androgen production.

Researchers generated a new transgenic mouse model of polycystic ovary syndrome (PCOS), named Greywick (Gw).

The FDA has cleared an IND application for Gan & Lee Pharmaceuticals' GZR-4 allowing initiation of a phase I trial in the U.S.

The National Institute of Pharmaceutical R&D (Beijing) has identified condensed heterocyclic compounds acting as insulin secretagogues and gluconeogenesis inhibitors reported to be useful for the treatment of diabetes.

Vaxxinity has selected VXX-401 to pursue as its anti-proprotein convertase subtilisin/kexin type 9 serine protease (PCSK9) vaccine candidate to treat hypercholesterolemia, and reported data demonstrating durable lowering of low-density lipoprotein (LDL) cholesterol in nonhuman primates.

Classic galactosemia (CG) is an inborn error of galactose metabolism caused by a severe deficiency of galactose-1-phosphate:uridylyltransferase (GALT) enzymatic activity, which leads to accumulation of several metabolites such as galactose-1-phosphate (Gal-1-P), the substrate of GALT, and galactonate and galactitol, the oxidation and reduction products.

Researchers from Alnylam Pharmaceuticals and collaborators published data from a study that aimed to identify novel therapeutic targets for abdominal obesity by searching for genetic variants associated with lower waist-to-hip ratio.

A research team at Shanghai University and Shaanxi University of Chinese Medicine has discovered a novel lipid-lowering compound with hepatoprotective effects.